Dutch biotech Citryll nabs €85M to position inflammatory antibody for a...
Citryll, a Dutch biotech that has largely flown under the radar for most of its nearly 10-year history, has patched together an €85 million Series B to test a monoclonal antibody in two inflammatory...
View ArticleADC scientist who paved the way for Daiichi’s Enhertu dies
The “scientific trailblazer” behind Daiichi Sankyo’s blockbuster ADC medicines, Toshinori Agatsuma, has passed away, the company said Monday. Agatsuma was head of research at the Japanese drugmaker,...
View ArticleDimension nabs $500M second fund for 'still contrary' intersection of bio and...
Dimension has crossed a key threshold. The VC firm's trio of New York and Bay Area managing partners has raised a sophomore fund in the arduous field of life sciences investing. That group — Zavain Dar...
View ArticleEnanta's mid-stage win in pediatric RSV; Carisma to lay off 34% of staff
Plus, news about Innovent Biologics, Relmada Therapeutics, Zevra Therapeutics, Incyte and Bionical Emas: Enanta’s Ph2 win in RSV: The company’s oral N-protein inhibitor achieved a 1.4 log decline in...
View ArticleAmazon Pharmacy, Ro say they help patients stick with GLP-1 drugs longer
Patients who get their GLP-1 weight loss medication prescriptions filled at Amazon Pharmacy are more likely to keep taking the medications than other published research shows, Amazon Pharmacy Vice...
View ArticleMerck's Keytruda combo misses overall survival in Phase 3 trial in ovarian...
Merck said a Keytruda regimen hit the primary endpoint of progression-free survival in a Phase 3 study that enrolled certain patients with ovarian cancer, but it failed to hit the secondary endpoint of...
View ArticleAbbVie declares third Phase 3 Parkinson’s win from Cerevel takeover
There’s a silver lining for AbbVie on its closely-followed buyout of Cerevel: The pharma company reported Monday that its Parkinson’s disease candidate notched another win. This comes after it said...
View Article#ASH24: AbbVie, Genmab tout Epkinly combinations in earlier lines of...
SAN DIEGO — AbbVie and Genmab are building the case for their bispecific Epkinly in earlier lines of treatment, presenting longer-term combination data in two types of non-Hodgkin lymphoma. At the...
View ArticleICER finds Vertex's non-opioid pain treatment could bring cost savings at a...
The cost-effectiveness watchdog ICER found that Vertex’s future non-opioid treatment for acute pain could be cost-saving, but only at a low price, according to a draft report released on Monday by the...
View Article#ASH24: GSK reports Blenrep overall survival data in multiple myeloma as it...
SAN DIEGO — Two years after pulling Blenrep from the market, GSK is positioning for a relaunch. This time, the company says it’s coming from a “fundamentally different starting point,” including new...
View ArticleVijay Pande hands a16z biotech leadership to Vineeta Agarwala
The biotech and life sciences team at a16z is getting a new leader, as founding investor Vijay Pande moves into a role focused on artificial intelligence and its healthcare applications, Endpoints News...
View ArticleAgios' stock drops after disclosing new liver-related safety warning in...
Agios Pharmaceuticals on Monday saw its stock price drop by more than 24% as it disclosed that its oral candidate for the blood disorder thalassemia has been submitted to regulators worldwide for...
View ArticleBelharra Therapeutics sticks with lead programs, trims workforce by 40%
San Diego startup Belharra Therapeutics, a biotech creating small molecule cancer and immunology medicines, has laid off 21 employees, Endpoints News has confirmed. Belharra, from the same team as...
View ArticlePerson of interest arrested in connection with UnitedHealthcare CEO killing
Authorities have arrested a person of interest in connection with the fatal shooting of UnitedHealthcare CEO Brian Thompson. The arrest came after a days-long manhunt for the person who gunned down...
View ArticleSupreme Court won't take up PhRMA-Arkansas 340B expansion case
The US Supreme Court on Monday said it won't hear a case related to the expansion of the federal 340B drug discount program that pitted the industry group PhRMA against the ...
View ArticleTrump elevates disproven vaccines-autism link in interview
In his first major interview since securing another term in the White House, President-elect Donald Trump reiterated concerns with the disproven link between childhood vaccines and autism, a nod to the...
View ArticleRelation and GSK to collaborate on fibrosis, osteoarthritis
Machine learning and AI have sparked a transformation in drug discovery, but cracking the biology is still paramount. That's the thinking behind a new collaboration between UK startup Relation...
View Article#ASH24: Retrospective analysis shows potential for GLP-1s to treat blood clots
SAN DIEGO — As researchers explore more potential benefits of GLP-1 medicines, a new retrospective study is suggesting the drug class’ potential to treat venous thromboembolisms, or blood clots in the...
View Article#ASH24: Kura Oncology details 'aggressive' approach in first-line AML
SAN DIEGO — As Kura Oncology awaits key pivotal data in relapsed or refractory acute myeloid leukemia, the company is going all in on combinations in the frontline setting. On Monday, Kura and its...
View Article#ASH24: Arcellx and Gilead seek to unseat J&J/Legend in multiple myeloma
SAN DIEGO — Gilead and Arcellx say their experimental multiple myeloma cell therapy anito-cel could be a safer rival to field leaders Legend Biotech and Johnson & Johnson. New results from a...
View Article